17:29 , May 11, 2018 |  BC Week In Review  |  Clinical News

FDA committee votes against Mallinckrodt's jaundice candidate in newborns

FDA's Gastrointestinal Drugs Advisory Committee and Pediatric Advisory Committee voted 21-3 that the risk-benefit profile of stannsoporfin does not support its approval to treat newborns ≥35 weeks who are at risk of developing hyperbilirubinemia, or...
21:02 , Mar 2, 2018 |  BC Week In Review  |  Clinical News

FDA reviewing Mallinckrodt's neonatal jaundice candidate

Mallinckrodt plc (NYSE:MNK) said FDA accepted for review an NDA for stannsoporfin to treat neonates at risk for developing severe hyperbilirubinemia, or jaundice. The PDUFA date is Aug. 22. The heme oxygenase inhibitor has Fast Track...
18:16 , Aug 16, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Stroke Rat studies suggest polymeric micelles loaded with a HMOX1-encoding vector could help treat ischemic stroke. The polymeric micelles consisted of deoxycholic acid-conjugated polyethylenimine polymers loaded with a plasmid encoding HMOX1. In a middle cerebral...
08:00 , Jan 28, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2; NRF2); heme oxygenase decycling 1 (HMOX1; HO-1; Hsp32)

Inflammation INDICATION: Inflammation Cell culture and mouse studies identified two activators of the anti-inflammatory NFE2L2/HMOX1 pathway that could help treat inflammation. Chemical synthesis and hemoglobin-based assays of compounds linking diverse NFE2L2 inducers to cobalt-carbon monoxide complexes...
07:00 , Jun 18, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Activating transcription factor 4 (ATF4); heme oxygenase decycling 1 (HMOX1; HO-1; Hsp32)

Cancer INDICATION: Cancer Cell culture, mouse and patient sample studies suggest inhibiting ATF4 could help treat cancer. In patients with breast or sarcomal tumors, levels of ATF4 and the antioxidant protein HMOX1 were higher in metastatic tumors...
08:00 , Feb 20, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Parkinson's disease (PD) Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2; NRF2); heme oxygenase decycling 1 (HMOX1; HO-1; Hsp32) ...
07:00 , Aug 30, 2012 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Transgenic mouse model for schizophrenia Transgenic mice with astrocyte-specific overexpression of human heme oxygenase decycling 1 (HMOX1; HO-1;...
07:00 , Apr 9, 2012 |  BC Week In Review  |  Company News

Osta Biotechnologies cancer, neurology news

Osta will delay the filing of its 2011 financial statements due to limited financial resources. The company said it continues to seek strategic alternatives or financing, including by way of debt, equity or strategic partnership....
08:00 , Jan 5, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Malaria; Salmonella Heme oxygenase decycling 1 (HMOX1; HO-1; Hsp32) Mouse studies suggest inhibiting HO-1 could protect...
07:00 , Aug 25, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Fumarate hydratase (FH); heme oxygenase decycling 1 (HMOX1; HO-1) Cell culture studies suggest inhibiting HMOX1 could...